Serina Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
Serina Therapeutics, Inc. (NYSE American: SER) filed this Form 8-K on March 25, 2026, to announce its financial results for the fiscal year ended December 31, 2025. The company is incorporated in Delaware and operates from Huntsville, Alabama.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K serves as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1, but the numerical data is not embedded within the body of this current report.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in the text of this filing. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year analysis.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document explicitly states that the information in Item 2.02 and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual financial figures for the year ended December 31, 2025.
- Verify the company's cash position and burn rate given the lack of specific liquidity data in this summary.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the full press release.
- Check for any new debt covenants or financing activities disclosed in the full exhibit.